Having trouble accessing articles? Reset your cache.

Rinvoq approval bolsters AbbVie's autoimmune portfolio

With Humira adalimumab set to face increasing biosimilar competition internationally this year, AbbVie has notched its second U.S. regulatory win for a successor to its primary revenue driver with FDA’s approval Rinvoq upadacitinib on Friday for rheumatoid arthritis.

The oral

Read the full 396 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers